Doi, Toshihiko http://orcid.org/0000-0003-2042-6829
Fujiwara, Yutaka
Shitara, Kohei
Shimizu, Toshio http://orcid.org/0000-0002-3828-9669
Yonemori, Kan
Matsubara, Nobuaki
Ohno, Izumi
Kogawa, Takahiro
Naito, Yoichi
Leopold, Lance
Munteanu, Mihaela
Yatsuzuka, Naoyoshi
Han, Shi Rong
Samkari, Ayman
Yamamoto, Noboru
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA (N/A)
Incyte Corporation, Wilmington, DE, USA (N/A)
Article History
Received: 4 February 2020
Accepted: 17 April 2020
First Online: 20 June 2020
Compliance with ethical standards
:
: T.D. received grants and personal fees from Eli Lilly, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Boehringer Ingelheim, Chugai Pharma, Bristol-Myers Squibb, AbbVie, personal fees from Amgen, Takeda, Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharma, Oncolys BioPharma, grants from Merck Serono, Janssen, Pfizer, Quintiles, and Eisai.Y.F. received grants from MSD, AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Incyte, and Novartis for research funding; personal fees from AstraZeneca for advisory role and participation in speakers’ bureau, personal fees from Daiichi Sankyo for advisory role.K.S. reports paid consulting or advisory roles for Astellas Pharma, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho, Novartis, AbbVie, and GlaxoSmithKline; honoraria from Novartis, AbbVie, and Yakult; and research funding from Astellas, Lilly, Ono Pharmaceutical, Sumoitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD and Medi Science.T.S. received research grant (Institute) from Novartis, Eli Lilly, Bristol-Myers Squibb, Daiichi Sankyo, Takeda Oncology, Eisai, AstraZeneca, AbbVie, Incyte, Astellas Pharma, Symbio Pharmaceuticals, 3D-Medicine, Five Prime, PharmaMar, and Chordia Therapeutics.K.Y. received personal fees for advisory role and lecture from Eisai, personal fees for advisory role from Novartis, Chugai, and Ono Pharmaceutical, lecture fee from Taiho, personal fee for lecture from Pfizer.N.M. received grants and personal fees from Janssen, MSD, Astra-Zeneca, grants from Roche, Lilly, Taiho, Bristol-Myers Squibb, and personal fees from Sanofi.I.O., S.R.H., T.K., M.M., N.Yatsuzuka: have nothing to disclose.L.L. reports employment at Incyte Corporation.A.S. reports employment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.Y.N. received other for participation in speakers’ bureau from Pfizer, Taiho, Nippon Kayaku, Eli Lilly, AstraZeneca, Merck Serono, Bayer, Meiji Seika, Roche Diagnostics, Novartis, Taiho, Chugai Pharmaceutical, Eisai, and Fuji Film Toyama Chemistry; other for research funding from Roche Diagnostics.N.Yamamoto received research grants from Chugai, Taiho, Eisai, Lilly, Quintiles, Astellas, Bristol-Myers Squibb, Novartis, Daiichi Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Bayer, Ono Pharmaceutical, Takeda, Janssen Pharmaceutical, MSD, Merck, GSK, honoraria from Ono Pharmaceutical, Chugai, AstraZeneca, Pfizer, Lilly, Bristol-Myers Squibb, Sysmex, personal fees for consulting from Eisai, Otsuka, Takeda, Boehringer Ingelheim, and Cimic.
: The study protocol and all amendments were approved by the institutional review board or ethics committee at each center. The study was conducted in accordance with the protocol and its amendments, all relevant local and national regulations, the provisions of the Declaration of Helsinki, and Good Clinical Practice guidelines.
: All participants provided written and informed consent before enrollment.
: The data sharing policy of Merck Sharp & Dohme, including restrictions, is available at ExternalRef removed. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.